What is Gameto?
Founded by Dr. Dina Radenkovic and Martin Varsavsky, Gameto operates at the intersection of biotechnology and reproductive health. The company utilizes a sophisticated cell engineering platform to develop novel therapeutic programs aimed at addressing significant unmet needs in women's health. By integrating deep scientific expertise with a robust understanding of the fertility landscape, Gameto is effectively transforming how reproductive conditions are managed and treated. Its market position is bolstered by a strategic focus on democratizing access to advanced fertility solutions, moving beyond traditional clinical models to offer scalable, technology-driven interventions that improve patient outcomes on a global scale.
How much funding has Gameto raised?
Gameto has raised a total of $158M across 5 funding rounds:
Series A
$20M
Other Financing Round
$17M
Series B
$33M
Series C
$44M
Stock/Share Issuance
$44M
Series A (2022): $20M with participation from Anne Wojcicki, Plum Alley, Future Ventures, BOLD Capital Partners, Lux Capital, TA Ventures, Overwater Ventures, and Robert Nelsen
Other Financing Round (2022): $17M led by BOLD Capital Partners, Arcadia Investment Partners, Insight Partners, Plum Alley, and Future Ventures
Series B (2024): $33M supported by BOLD Capital Partners, RA Capital Management, Insight Partners, Two Sigma Ventures, and Future Ventures
Series C (2025): $44M featuring RA Capital Management, Two Sigma Ventures, Arcadia Investment Group, Overwater Ventures, Insight Partners, and BOLD Capital Partners
Stock/Share Issuance (2025): $44M, investors not publicly disclosed
Key Investors in Gameto
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing their TechAtlas think tank to support scientific innovation.
Two Sigma Ventures
An early-stage venture capital firm that invests in transformative companies leveraging information growth, computing power, and data science to drive human potential.
BOLD Capital Partners
A venture capital firm dedicated to investing in entrepreneurs and technologies that aim to transform the world by addressing significant human challenges through science and innovation.
What's next for Gameto?
With the successful closure of this latest financing round, Gameto is well-positioned to accelerate its R&D pipeline and scale its operational capabilities. The company's strategic roadmap likely involves transitioning its lead programs through critical clinical milestones while expanding its intellectual property portfolio. As the firm matures, the focus will shift toward commercialization readiness and the potential integration of its cell engineering technologies into broader healthcare ecosystems. Continued support from high-conviction investors suggests a long-term commitment to disrupting the fertility market, with an emphasis on sustainable growth and the delivery of breakthrough therapies that redefine the standard of care for women worldwide.
See full Gameto company page
